Combinations and modes of administration of therapeutic agents and combination therapy
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/127
A61K-038/16
출원번호
US-0228323
(2011-09-08)
등록번호
US-8268348
(2012-09-18)
발명자
/ 주소
Desai, Neil P.
Soon-Shiong, Patrick
출원인 / 주소
Abraxis Bioscience, LLC
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
37인용 특허 :
66
초록▼
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radi
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
대표청구항▼
1. A method for treating non-small cell lung cancer (NSCLC) in a human individual comprising intravenously administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, and b) an effective amount of carboplatin, wherein t
1. A method for treating non-small cell lung cancer (NSCLC) in a human individual comprising intravenously administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, and b) an effective amount of carboplatin, wherein the nanoparticle composition is free of cremophor. 2. The method of claim 1, wherein dosage of paclitaxel in the nanoparticle composition is about 50 to about 400 mg/m2. 3. The method of clam 2, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is in the range of 50-250 mg/m2. 4. The method of claim 3, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is in the range of 100-150 mg/m2. 5. The method of claim 4, wherein the carboplatin is administered once every three weeks. 6. The method of claim 5, wherein the carboplatin is administered at the dose of AUC=6. 7. The method of claim 6, wherein the NSCLC is advanced. 8. The method of claim 7, wherein the NSCLC is first line advanced NSCLC. 9. The method of claim 6, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 10. The method of claim 6, wherein the albumin is human serum albumin. 11. The method of claim 10, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 12. The method of claim 11, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1. 13. The method of claim 4, wherein the NSCLC is advanced. 14. The method of claim 13, wherein the NSCLC is first line advanced NSCLC. 15. The method of claim 14, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 16. The method of claim 4, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 17. The method of claim 4, wherein the albumin is human serum albumin. 18. The method of claim 17, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 19. The method of claim 18, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1. 20. The method of claim 1, wherein the carboplatin is administered once every three weeks. 21. The method of claim 20, wherein the carboplatin is administered at the dose of AUC=6. 22. The method of claim 1, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is 100 mg/m2, and the carboplatin is administered once every three weeks and at the dose of AUC=6. 23. The method of claim 22, wherein the NSCLC is advanced. 24. The method of claim 23, wherein the NSCLC is first line advanced NSCLC. 25. The method of claim 24, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 26. The method of claim 24, wherein the albumin is human serum albumin. 27. The method of claim 26, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 28. The method of claim 27, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1. 29. The method of claim 22, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 30. The method of claim 1, wherein the NSCLC is advanced. 31. The method of claim 30, wherein the NSCLC is first line advanced NSCLC. 32. The method of claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 33. The method of claim 1, wherein the albumin is human serum albumin. 34. The method of claim 33, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 35. The method of claim 34, wherein the weight ratio of the albumin and paclitaxel in the nanoparticle composition is about 9:1. 36. A method for treating non-small cell lung cancer (NSCLC) in a human individual comprising intravenously administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with human serum albumin, wherein the nanoparticle composition is free of cremophor, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, wherein the nanoparticle composition is administered on a weekly schedule and the dosage of paclitaxel in the nanoparticle composition is 100 mg/m2, and b) an effective amount of carboplatin, wherein the carboplatin is administered once every three weeks and at the dose of AUC=6. 37. The method of claim 36, wherein the weight ratio of the human serum albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 38. The method of claim 37, wherein the weight ratio of the human serum albumin and paclitaxel in the nanoparticle composition is about 9:1. 39. The method of claim 36, wherein the NSCLC is advanced. 40. The method of claim 39, wherein the NSCLC is first line advanced NSCLC. 41. The method of claim 40, wherein the weight ratio of the human serum albumin and paclitaxel in the nanoparticle composition is about 9:1 or less. 42. The method of claim 41, wherein the weight ratio of the human serum albumin and paclitaxel in the nanoparticle composition is about 9:1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (66)
Baca, Manuel; Wells, James A., Anti-VEGF antibodies.
Muller Marcel,CHX ; Geiger Thomas,DEX ; Altmann Karl-Heinz,CHX ; Fabbro Doriano,CHX ; Dean Nicholas M. ; Monia Brett ; Bennett Clarence Frank, Combination for treatment of proliferative diseases.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
De, Tapas; Desai, Neil P.; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Bendig Mary M. (London GBX) Kettleborough Catherine A. (Herts GBX) Saldanha Jose (Middlesex GBX), Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell.
Goldman, Mitchel P.; Weiss, Robert A.; Zikorus, Arthur W.; Chandler, James G., Method and apparatus for applying energy to biological tissue including the use of tumescent tissue compression.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Method for the preparation of fluorocarbon-containing polymeric shells for medical imaging.
Brown Paul A. ; Bursten Stuart L. ; Rice Glenn C. ; Singer Jack W., Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF, and VEGF.
Heimbrook David C. (Ringoes NJ) Oliff Allen I. (Gwynedd Valley PA) Stirdivant Steven M. (Warrington PA) Ahern Janet (Horsham PA), Method of treating bladder cancer cells.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for in vivo delivery of nutriceuticals and compositions useful therefor.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of blood substitutes for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of immunostimulating agents for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of nucleic acids for in vivo delivery.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of pharmaceutically active agents for in vivo delivery.
Bagchi Pranab (Webster NY) Stewart Robert C. (Spencerport NY) McIntire Gregory L. (West Chester PA) Minter John R. (Rochester NY), Microprecipitation of micro-nanoparticulate pharmaceutical agents.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Non-fluorinated polymeric shells for medical imaging.
Zenke Gerhard,DEX ; Schuurman Hendrik,CHX ; Haeberlin Barbara,CHX ; Meinzer Armin,DEX, Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Magdassi Shlomo,ILX ; Yang Andrew ; Tao Chunlin ; Desai Neil P. ; Yao Zhiwen ; Soon-Shiong Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
Magdassi, Shlomo; Yang, Andrew; Tao, Chunlin; Desai, Neil P.; Yao, Zhiwen; Soon-Shiong, Patrick, Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; LaBell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; LaBell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C., Bendamustine derivatives and methods of using same.
Bakale, Roger P.; Brown, Peter D.; Chen, Jian; Drager, Anthony S.; Labell, Rachel Y.; McKean, Robert E.; Patel, Piyush R.; Roemmele, Renee C.; McIntyre, Bradley, Bendamustine derivatives and methods of using same.
De, Tapas; Desai, Neil P; Yang, Andrew; Yim, Zachary; Soon-Shiong, Patrick, Compositions and methods for preparation of poorly water soluble drugs with increased stability.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.